A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Squamous Non Small Cell Lung Carcinoma (sqNSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Erdafitinib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms FIND Trial
- 11 Oct 2018 New trial record
- 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer.
- 26 Sep 2018 The study is under development and is currently targeted to start recruitment in Q2/2018